Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/24417
Tüm üstveri kaydı
Dublin Core Alanı | Değer | Dil |
---|---|---|
dc.date.accessioned | 2022-02-11T09:47:05Z | - |
dc.date.available | 2022-02-11T09:47:05Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | Filiz, G. vd. (2010): "Significance of nm23 immunoexpression in the prognosis of renal cell carcinoma". Journal of International Medical Research, 38(2), 620-624. | en_US |
dc.identifier.issn | 0300-0605 | - |
dc.identifier.issn | 1473-2300 | - |
dc.identifier.uri | https://doi.org/10.1177/147323001003800224 | - |
dc.identifier.uri | https://journals.sagepub.com/doi/10.1177/147323001003800224 | - |
dc.identifier.uri | http://hdl.handle.net/11452/24417 | - |
dc.description.abstract | Non-metastatic gene 23 (nm23) is a metastasis suppressor gene that is expressed in all tissues and decreased nm23 expression may be linked to poor prognosis. By immunohistochemical staining of nm23 protein antibodies this study examined the prognostic value of nm23 protein expression in 54 renal cell carcinoma (RCC) patients and analysed its relationship with tumour, node, metastases (TNM) surgical stage, Fuhrman nuclear grade, lymph node involvement and survival. Of the 54 RCC cases studied, 11 (20.4%) showed positive lymph node involvement while 43 (79.6%) were lymph node negative. There was no difference in nm23 protein expression between cases with and without lymph node involvement. In addition, nm23 protein expression was not related to TNM stage, Fuhrman nuclear grade or survival. More extensive studies are required to understand the effect of nm23 protein expression on the biological behaviour of RCC. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Sage Publications | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Renal cell carcinoma | en_US |
dc.subject | NM23 | en_US |
dc.subject | Immunohistochemistry | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Expression | en_US |
dc.subject | Protein | en_US |
dc.subject | Metastasis | en_US |
dc.subject | Association | en_US |
dc.subject | Cancer | en_US |
dc.subject | Stage | en_US |
dc.subject | Research & experimental medicine | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.title | Significance of nm23 immunoexpression in the prognosis of renal cell carcinoma | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000279877200024 | tr_TR |
dc.identifier.scopus | 2-s2.0-77953692852 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Patoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Üroloji Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 620 | tr_TR |
dc.identifier.endpage | 624 | tr_TR |
dc.identifier.volume | 38 | tr_TR |
dc.identifier.issue | 2 | tr_TR |
dc.relation.journal | Journal of International Medical Research | en_US |
dc.contributor.buuauthor | Filiz, Gülaydan | - |
dc.contributor.buuauthor | Adım, Şaduman Balaban | - |
dc.contributor.buuauthor | Aytaç, Berna | - |
dc.contributor.buuauthor | Akar, Eylem | - |
dc.contributor.buuauthor | Vuruşkan, Hakan | - |
dc.contributor.researcherid | AAH-9746-2021 | tr_TR |
dc.identifier.pubmed | 20515575 | tr_TR |
dc.subject.wos | Medicine, research & experimental | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | Pubmed | en_US |
dc.wos.quartile | Q4 | en_US |
dc.contributor.scopusid | 6602693514 | tr_TR |
dc.contributor.scopusid | 15730076300 | tr_TR |
dc.contributor.scopusid | 56527372000 | tr_TR |
dc.contributor.scopusid | 26634688200 | tr_TR |
dc.contributor.scopusid | 6507328150 | tr_TR |
dc.subject.scopus | Nucleoside-Diphosphate Kinase; Suppressors; Prunes | en_US |
dc.subject.emtree | Non metastatic gene 23 protein | en_US |
dc.subject.emtree | Tumor suppressor protein | en_US |
dc.subject.emtree | Unclassified drug | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cancer classification | en_US |
dc.subject.emtree | Cancer staging | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Fuhrman nuclear grade | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human tissue | en_US |
dc.subject.emtree | Immunohistochemistry | en_US |
dc.subject.emtree | Immunoreactivity | en_US |
dc.subject.emtree | Kidney carcinoma | en_US |
dc.subject.emtree | Lymph node metastasis | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Prognosis | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Protein localization | en_US |
dc.subject.emtree | Survival time | en_US |
dc.subject.emtree | Tumor suppressor gene | en_US |
Koleksiyonlarda Görünür: | Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.